pcvx-20260713 0001649094 FALSE 825 Industrial Road Suite 300 San Carlos California 0001649094 2026-07-13 2026-07-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________________________ FORM 8-K _____________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2026 _____________________________________________ Vaxcyte, Inc. (Exact name of Registrant as Specified in Its Charter) _____________________________________________ Delaware 01-39323 46-4233385 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 825 Industrial Road Suite 300 San Carlos , California 94070 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 650 ) 837-0111 Not Applicable (Former Name or Former Address, if Changed Since Last Report) _____________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share PCVX The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 13, 2026, Heath Lukatch notified the Board of Directors (the “Board”) of Vaxcyte, Inc. (“the “Company”) of his retirement from the Board, effective as of July 16, 2026. Dr. Lukatch’s retirement was not the result of any disagreement or dispute with the Company. The Company thanks Dr. Lukatch for his considerable contributions over more than eight years of Board service. Concurrently, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed John Markels to the Board as a Class II director, effective as of July 16, 2026. Dr. Markels’ term will expire at the Company’s annual meeting of stockholders in 2028. The Board also appointed Dr. Markels to serve as a member of the Audit Committee and Compensation Committee of the Board. The Board has determined that Dr. Markels qualifies as an independent director under the independence requirements set forth under Rule 5605(a)(2) of the Nasdaq Rules and listing standards. There are no arrangements or understandings between Dr. Markels and any other persons pursuant to which he was selected as a director. Additionally, there are no transactions involving the Company and Dr. Markels that the Company would be required to report pursuant to Item 404(a) of Regulation S-K. Dr. Markels will receive compensation in accordance with the Company’s non-employee director compensation program as in effect from time to time (the “Director Compensation Program”), as most recently described under the section titled “Non-Employee Director Compensation” in the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 23, 2026; provided, however, that the equivalent value of the annual equity grant for all directors is currently set at $430,000. The Company has entered into its standard form of indemnification agreement with Dr. Markels. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. VAXCYTE, INC. Date: July 15, 2026 By: /s/ Andrew Guggenhime Andrew Guggenhime President and Chief Financial Officer

Heath Lukatch retired from Vaxcyte's Board of Directors effective July 16, 2026, after over eight years of service. John Mar was appointed to the Board following a recommendation from the Nominating and Corporate Governance Committee.

On July 13, 2026, Heath Lukatch informed the Board of Directors of Vaxcyte, Inc. about his retirement from the Board, which will take effect on July 16, 2026. His departure is amicable and not due to any disagreements with the company. Dr. Lukatch has served on the Board for over eight years, and the company expressed gratitude for his significant contributions during this time. In conjunction with this change, the Board appointed John Mar, following a recommendation from the Nominating and Corporate Governance Committee.

Vaxcyte, Inc.

AI Executive Summary

Key Takeaways

Raw Filing Content

Filing Overview

What This Means